LucaDezzaniMD

Global Medical Director at Novartis Oncology

Dr. Dezzani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I am a Medical Doctor with more than 10 years’ experience in healthcare, both in clinical practice as a Physician and in the pharmaceutical industry. Over the span of my career, I have covered roles at the national, regional and global level in both Europe and North America. Through these experiences, I have built unique expertise in clinical development, medical affairs, and companion diagnostics in several disease areas, especially in oncology and hematology.
I have also enhanced my multicultural awareness, and my ability to work with colleagues and clients from diverse backgrounds.
Moreover, I have accumulated extensive experience in supporting other functions and understanding business needs, in particular: marketing, sales, regulatory, and market access. As part of my skillset, I have a well-recognized ability to work in matrix environments and I possess a highly effective leadership style

PubMed

2 citations
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.
David Queiroz Borges Muniz, Barbara Ratto, Hongbo Yang, Jing Zhao, Madeline Jenkins
Advances in Therapy. 2019-10-19
19 citations
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)
Manuela Schmidinger, Aristotelis Bamias, Giuseppe Procopio, Robert E. Hawkins, Angel Rodriguez Sanchez
The Oncologist. 2019-04-01
11 citations
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.
Cora N. Sternberg, Robert J. Motzer, Thomas E. Hutson, Toni K. Choueiri, Christian Kollmannsberger
Clinical Genitourinary Cancer. 2019-02-06

Journal Articles

"Frontline nilotinib in patients with Chronic Myeloid Leukemia in Chronic Phase: Results from the European ENEST1st study"
A Hochhaus, G Rosti, NCP Cross, JL Steegmann, P le Coutre, G Ossenkoppele, L Petrov, T Masszi, A Hellmann, L Griskevicius, W Wiktor-Jedrzejczak, D Rea, D Coriu, TH Bru..., Leukemia, 1/1/2015
"Cell fusion in tumor progression: the isolation of cell fusion products by physical methods"
Pedrazzoli F, Chrysantzas I, Dezzani L, Rosti V, Vincitorio M, Sitar G, Cancer Cell Int, 1/20/2011
"Mutations in the 5' UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2"
Pippucci T, Savoia A, Perrotta S, Pujol-Moix N, Noris P, Castegnaro G, Pecci A, Gnan C, Punzo F, Marconi C, Gherardi S, Loffredo G, De Rocco D, Scianguetta S, Barozzi ..., Am J Hum Genet, 1/1/2011

Lectures

"Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CMLCP): ENEST1st SubAnalysis"
1/1/2015
"Efficacy and Safety of Frontline Nilotinib In 1089 European Patients (PTS) with Chronic Myeloid Leukemia In Chronic Phase (CMLCP): ENEST1st Final Analysis"
1/1/2015

Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary CancersFebruary 1st, 2022
Eisai Inc. Announces the Appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business GroupMay 20th, 2019
Phase 2 Data for ERLEADA® (Apalutamide) plus Androgen Deprivation Therapy Following Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer Show 100% Biochemical Free Recurrence Rate More Than Two Years Post-SurgeryMay 4th, 2024